| Trends in medical aid in dying in Oregon and Washington L Al Rabadi, M LeBlanc, T Bucy, LM Ellis, DL Hershman, FL Meyskens, ... JAMA Network Open 2 (8), e198648-e198648, 2019 | 64 | 2019 |
| Everolimus plus exemestane treatment in patients with metastatic hormone receptor‐positive breast cancer previously treated with CDK4/6 inhibitor therapy MM Cook, L Al Rabadi, AJ Kaempf, MM Saraceni, MA Savin, ZI Mitri The Oncologist 26 (2), 101-106, 2021 | 43 | 2021 |
| A way forward for cancer chemoprevention: think local L Al Rabadi, R Bergan Cancer Prevention Research 10 (1), 14-35, 2017 | 24 | 2017 |
| Linear probe endobronchial ultrasound bronchoscopy with guided transbronchial needle aspiration (EBUS–TBNA) in the evaluation of mediastinal and hilar pathology: introducing … M Abu-Hijleh, Y El-Sameed, K Eldridge, E Vadia, H Chiu, Z Dreyfuss, ... Lung 191, 109-115, 2013 | 24 | 2013 |
| Phase II study of ipilimumab in men with metastatic prostate cancer with an incomplete response to androgen deprivation therapy JN Graff, MN Stein, R Surana, L Al Rabadi, E Liu, L Fong, S Bailey, ... Frontiers in Oncology 10, 1381, 2020 | 14 | 2020 |
| Everolimus and exemestane for the treatment of metastatic hormone receptor-positive breast cancer patients previously treated with CDK4/6 inhibitor based therapies. M Cook, L Al Rabadi, ZI Mitri Journal of Clinical Oncology 37 (15_suppl), 1058-1058, 2019 | 14 | 2019 |
| A way forward for cancer chemoprevention: think local. Cancer Prev Res (Phila) 2017; 10 (1): 14–35. DOI: 10.1158/1940–6207 L Al Rabadi, R Bergan CAPR-16–0194. PMID: 27780807, 2023 | 6 | 2023 |
| Ado-trastuzumab for the treatment of metastatic HER2-positive breast cancer in patients previously treated with Pertuzumab LS Al Rabadi, MM Cook, AJ Kaempf, MM Saraceni, MA Savin, ZI Mitri BMC cancer 21, 1-8, 2021 | 3 | 2021 |
| Thromboprophylaxis with fixed dose, 1mg/kg/day, low molecular weight heparin in adults undergoing induction with asparaginase for acute lymphoblastic leukemia. Results of a … LS Al Rabadi, SR Olson, JJ Shatzel, TG Deloughery, B Hayes-Lattin Blood, The Journal of the American Society of Hematology 130 (Suppl_1), 2397 …, 2017 | 3 | 2017 |
| Abstract P6-18-26: Ado-trastuzumab for the treatment of metastatic HER2-amplified breast cancer patients previously treated with pertuzumab LS Al Rabadi, A Kaempf, JY Lim, MM Saraceni, MA Savin, ZI Mitri Cancer Research 79 (4_Supplement), P6-18-26-P6-18-26, 2019 | | 2019 |
| Ado-trastuzumab for the treatment of metastatic HER2-amplified breast cancer patients previously treated with pertuzumab LS Al Rabadi, A Kaempf, JY Lim, MM Saraceni, MA Savin, ZI Mitri CANCER RESEARCH 79 (4), 2019 | | 2019 |
